Nektar’s Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb
Agreement with Daiichi Sankyo In May 2016, Nektar Therapeutics (NKTR) entered into a collaboration and licensing agreement with Daiichi Sankyo, under which Nektar granted exclusive commercialization rights for its product candidate, Onezeald, to Daiichi Sankyo in Europe. Onezeald is a long-acting topoisomerase-1 inhibitor in clinical development for treating adult patients with advanced breast cancer. Nektar […]
JPMorgan Upgrades Ophthotech: Stock Skyrockets
Ophthotech (OPHT) rose 11.6% for the week ended June 3, 2016, and outperformed the SPDR S&P 500 ETF (SPY). It was one of the top mid-cap performers.
Seattle Genetics’ Valuation: How Does It Compare?
We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.
XBI on a Downward Slope, but How Steep?
On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.